Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Clavijo

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Cancer Research|June 21, 2018
Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck CancersJialing Zhang, Tony Chen, Xinping Yang, et al.
JCI Insight|April 5, 2019
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapyLillian Sun, Paul E Clavijo, Yvette Robbins, et al.
Oncoimmunology|November 1, 2018
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell typesKristin C Hicks, Massimo Fantini, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|March 20, 2021
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cellsMaxwell Y Lee, Yvette Robbins, Cem Sievers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2019
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T CellsJay Friedman, Ellen C Moore, Paul Zolkind, et al.
Elife|July 8, 2020
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cellsYvette Robbins, Sarah Greene, Jay Friedman, et al.
Revista De Calidad Asistencial : Organo De La Sociedad Espanola De Calidad Asistencial|May 12, 2012
[Study of adverse events in private healthcare. Confidence project for patient safety]R Limón-Ramírez, J García-Rubio, J J Miralles-Bueno, et al.
Cancer Research Communications|October 11, 2024
Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell CarcinomaEthan L Morgan, Anthony D Saleh, Shaleeka Cornelius, et al.
Science Immunology|December 12, 2025
Hypoxia-induced EGR1 remodels neutrophils to suppress antitumor immunityTian-Gen Chang, Jay Friedman, Paul E Clavijo, et al.
Cancer Research|October 13, 2021
Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in MacrophagesJulio C Valencia, Rebecca A Erwin-Cohen, Paul E Clavijo, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Cancer Research|June 21, 2018
Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck CancersJialing Zhang, Tony Chen, Xinping Yang, et al.
JCI Insight|April 5, 2019
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapyLillian Sun, Paul E Clavijo, Yvette Robbins, et al.
Oncoimmunology|November 1, 2018
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell typesKristin C Hicks, Massimo Fantini, Renee N Donahue, et al.
Journal for Immunotherapy of Cancer|March 20, 2021
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cellsMaxwell Y Lee, Yvette Robbins, Cem Sievers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2019
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T CellsJay Friedman, Ellen C Moore, Paul Zolkind, et al.
Elife|July 8, 2020
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cellsYvette Robbins, Sarah Greene, Jay Friedman, et al.
Revista De Calidad Asistencial : Organo De La Sociedad Espanola De Calidad Asistencial|May 12, 2012
[Study of adverse events in private healthcare. Confidence project for patient safety]R Limón-Ramírez, J García-Rubio, J J Miralles-Bueno, et al.
Cancer Research Communications|October 11, 2024
Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell CarcinomaEthan L Morgan, Anthony D Saleh, Shaleeka Cornelius, et al.
Science Immunology|December 12, 2025
Hypoxia-induced EGR1 remodels neutrophils to suppress antitumor immunityTian-Gen Chang, Jay Friedman, Paul E Clavijo, et al.
Cancer Research|October 13, 2021
Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in MacrophagesJulio C Valencia, Rebecca A Erwin-Cohen, Paul E Clavijo, et al.
Pageof 6